Group items tagged

he development of next-generation sequencing (NGS) over the past 15 to 20 years has seen multiple technologies rapidly leapfrogging each other's milestones to sequence more DNA faster, cheaper, and more accurately. While Illumina sequencers still predominate, other NGS providers are gaining ground, providing important alternative options for sequencing mechanisms, read lengths, run times, ease-of-use, and scalability. This article aims to guide researchers through the main differences among today's common NGS platforms, with a special focus on the offerings from Capitalbio Technology.

Epilepsy-related Gene Detection The Epilepsy-related gene testing of CapitalBio Technology is based on BES4000 semi-conductor sequencing platform, using target region capture and NGS technology together to detect the genes related epilepsy.

GJB2 Gene Coding Region and Splicing Site Detection This test is based on NGS technology, by detecting SNV、small InDel (<20bp) of GJB2 exon and 10bp intron of its upstream and downstream, can provide information as if the subject carrying GJB2 gene related deafness mutations.

Hereditary Deafness Gene Detection (227 Genes+Mitochondrial Genome) This test is based on NGS technology, it can detect 227 nuclear genomes + mitochondrial genome sequence, covering reported non-syndromic deafness and syndrome deafness.